Results 131 to 140 of about 9,786 (244)
Prophylactic neuroprotection against stroke: Low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function [PDF]
, 2011 Yanxin Zhao, David A. Rempe
openalex +1 more source
Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β‐thalassaemia: results from the ESCALATOR study [PDF]
, 2011 Alì Taher +8 more
openalex +1 more source
Caspian Journal of Internal Medicine, 2017 Background: Cardiac complications due to iron overload are the most common cause of death in patients with thalassemia major. The aim of this study was to compare iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and ...
Shahla Ansari +4 more
doaj
Oral iron chelation therapy with deferiprone in patients with Thalassemia Major [PDF]
, 2009 OBJECTIVE: To determine the efficacy and adverse effects of deferiprone in patients with Thalassemia Major. METHODS: A prospective case series study was conducted at the Fatimid Foundation Blood Bank and Haematological Diseases center Lahore.
Adil, Salman +3 more
core +1 more source
Long‐term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease [PDF]
, 2011 Elliott Vichinsky +16 more
openalex +1 more source
Journal of Asthma and Allergy, 2020 Mongkhon Sompornrattanaphan,1 Thanachit Krikeerati,1,2 Chamard Wongsa,1 Torpong Thongngarm,1 Kittika Yampayon3 1Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok ...
Sompornrattanaphan M +4 more
doaj